Demographic, clinical, serological characteristics and MGFA classification of individual participants

Participant (Group-number)SexAgeNaïveUMSMDNMGFADisease duration (months)AchR-Ab titer (nmol/L)Thymoma or thymic hyperplasiaUsed in Nanostring analysis
1-1F7165.65.423.55.5CSR104.9YesYes
1-2M5964.24.326.45.2CSR239.77YesYes
1-3M6593.12.13.61.2CSR89YesNo
1-4F4881.85.29.53.5CSR6.518NoNo
1-5M6978.14.314.92.7CSR233.85YesYes
1-6F8553.99.424.312.4CSR110.23NoNo
1-7M3671.57.516.54.5CSR50.67NoNo
1-8M7583.75.17.53.7CSR54.04NoNo
2-1M4366.87.217.19.0PR8(−)NoNo
2-2M8084.44.28.23.2PR20.76NoNo
2-3F4166.54.420.38.8PR210.24NoNo
2-4M6263.78.323.05.0PR6(−)NoNo
2-5F8021.25.246.726.9PR57.88NoNo
2-6F4555.611.725.07.7PR1.511.87YesNo
2-7M6040.46.225.727.7PR3.57.09YesNo
2-8F4282.32.412.33.0MM116.05NoYes
2-9M7230.46.138.924.5MM1217.65NoYes
2-10F5657.32.023.816.9MM0.56.36YesYes
2-11F7982.22.612.72.5PR31.91NoNo
2-12M7728.58.442.021.1PR47.44NoNo
2-13M5056.92.524.815.7PR114.66YesNo
3-1M5447.16.240.26.5N/AN/AN/AN/AYes
3-2F6778.85.612.43.2N/AN/AN/AN/ANo
3-3F6988.03.25.13.8N/AN/AN/AN/ANo
3-4F7884.32.79.63.4N/AN/AN/AN/ANo
3-5F6186.21.97.34.6N/AN/AN/AN/ANo
3-6M5361.79.220.38.9N/AN/AN/AN/ANo
3-7M5469.54.521.74.3N/AN/AN/AN/ANo
3-8M6060.36.030.43.3N/AN/AN/AN/AYes
3-9M6742.59.342.55.6N/AN/AN/AN/AYes
3-10F7076.03.513.07.6N/AN/AN/AN/ANo
4-1F6759.87.320.412.5V0.56.7YesYes
4-2F4674.96.813.05.3IIa109.76NoYes
4-3M4672.34.517.55.7IIb3.52.45YesYes

Every peripheral blood sample was analyzed by flow cytometry for B cell immunophenotyping. Memory B cells sorted from 3 patients per group were gathered into each pool and were submitted for Nanostring assay. UM, unswitched memory B cells; SM, switched memory B cells; DN, double-negative B cells; MGFA, Myasthenia Gravis Foundation of America; AchR-Ab, anti-acetylcholine receptor antibody; F, female; M, male; CSR, chronic stable remission; PR, pharmacologic remission; MM, minimal manifestation; N/A, not applicable.

Experimental Neurobiology 2019;28:720~726 https://doi.org/10.5607/en.2019.28.6.720
© Exp Neurobiol